Integrated Wealth Concepts LLC Boosts Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Integrated Wealth Concepts LLC lifted its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,129 shares of the biotechnology company’s stock after buying an additional 485 shares during the period. Integrated Wealth Concepts LLC’s holdings in Axon Enterprise were worth $7,244,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Westfield Capital Management Co. LP grew its position in Axon Enterprise by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after acquiring an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after purchasing an additional 83,265 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Axon Enterprise by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock worth $224,281,000 after purchasing an additional 9,090 shares during the last quarter. 1832 Asset Management L.P. increased its stake in shares of Axon Enterprise by 44.0% in the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after buying an additional 114,800 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Axon Enterprise by 13.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock valued at $108,496,000 after buying an additional 45,049 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Insider Activity

In other news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the completion of the transaction, the president now directly owns 208,166 shares in the company, valued at $126,179,820.90. This trade represents a 8.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brittany Bagley sold 4,338 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the transaction, the chief financial officer now owns 98,825 shares in the company, valued at approximately $37,449,733.75. The trade was a 4.20 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 135,256 shares of company stock worth $61,043,370. Insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Northland Securities raised their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. The Goldman Sachs Group raised their target price on Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. JMP Securities upped their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Craig Hallum lifted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Needham & Company LLC boosted their target price on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $460.33.

Axon Enterprise Trading Up 5.3 %

NASDAQ:AXON opened at $669.87 on Wednesday. The firm has a market capitalization of $51.08 billion, a P/E ratio of 173.09, a PEG ratio of 14.00 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a one year low of $229.02 and a one year high of $675.47. The company’s 50-day simple moving average is $493.10 and its 200 day simple moving average is $382.63.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.